Abstract:Glioblastoma multiforme (GBM) is the most aggressive and common malignant primary brain tumor. Patients with GBM often have poor prognoses, with a median survival of ∼15 months. Enhanced understanding of the molecular biology of central nervous system tumors has led to modifications in their classifications, the most recent of which classified these tumors into new categories and made some changes in their nomenclature and grading system. This review aims to give a panoramic view of the last 3 years' findings in glioblastoma characterization, its heterogeneity, and current advances in its treatment. Several molecular parameters have been used to achieve an accurate and personalized characterization of glioblastoma in patients, including epigenetic, genetic, transcriptomic and metabolic features, as well as age- and sex-related patterns and the involvement of several noncoding RNAs in glioblastoma progression. Astrocyte-like neural stem cells and outer radial glial-like cells from the subventricular zone have been proposed as agents involved in GBM of IDH-wildtype origin, but this remains controversial. Glioblastoma metabolism is characterized by upregulation of the PI3K/Akt/mTOR signaling pathway, promotion of the glycolytic flux, maintenance of lipid storage, and other features. This metabolism also contributes to glioblastoma's resistance to conventional therapies. Tumor heterogeneity, a hallmark of GBM, has been shown to affect the genetic expression, modulation of metabolic pathways, and immune system evasion. GBM's aggressive invasion potential is modulated by cell-to-cell crosstalk within the tumor microenvironment and altered expressions of specific genes, such as ANXA2, GBP2, FN1, PHIP, and GLUT3. Nevertheless, the rising number of active clinical trials illustrates the efforts to identify new targets and drugs to treat this malignancy. Immunotherapy is still relevant for research purposes, given the amount of ongoing clinical trials based on this strategy to treat GBM, and neoantigen and nucleic acid-based vaccines are gaining importance due to their antitumoral activity by inducing the immune response. Furthermore, there are clinical trials focused on the PI3K/Akt/mTOR axis, angiogenesis, and tumor heterogeneity for developing molecular-targeted therapies against GBM. Other strategies, such as nanodelivery and computational models, may improve the drug pharmacokinetics and the prognosis of patients with GBM.

Metabotropic Glutamate Receptors Type 3 and 5 Feature the “NeuroTransmitter-type” of Glioblastoma: A Bioinformatic Approach

Metabolic Signature-Based Subtypes May Pave Novel Ways for Low-Grade Glioma Prognosis and Therapy.

Tmic-18. Role Of Neurotransmitters In Glioblastoma Pathophysiology: Emerging Insights

Identification of Novel Human Glioblastoma-Specific Transcripts by Serial Analysis of Gene Expression Data Mining

A Novel Classifier Combining G Protein-Coupled Receptors and the Tumor Microenvironment is Associated with Survival Status in Glioblastoma.

Integrating Multi-Omics Analysis for Enhanced Diagnosis and Treatment of Glioblastoma: A Comprehensive Data-Driven Approach

The Translatome of Glioblastoma Multiforme

T Cell Features in Glioblastoma May Guide Therapeutic Strategies to Overcome Microenvironment Immunosuppression

An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment

Genome-Scale Metabolic Modeling of Glioblastoma Reveals Promising Targets for Drug Development

PRMT3 drives glioblastoma progression by enhancing HIF1A and glycolytic metabolism

Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma

The Interplay between Glioblastoma Cells and Tumor Microenvironment: New Perspectives for Early Diagnosis and Targeted Cancer Therapy

Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition

Molecular Characteristics in MRI-Classified Group 1 Glioblastoma Multiforme

Abstract 1666: Novel Glucose Transporter Inhibitors Decrease Glioblastoma Growth and Glucose Uptake

Metabolic Reprogramming in Glioblastoma Multiforme: A Review of Pathways and Therapeutic Targets

Tmic-82. Characterization Of Genetic Markers And Biological Processes Underlying The Transition Of Glioblastoma Cells From A Differentiated To A Stem-Cell-Like State

Pathway-based Classification of Glioblastoma Uncovers a Mitochondrial Subtype with Therapeutic Vulnerabilities.

Functional importance of glucose transporters and chromatin epigenetic factors in Glioblastoma Multiforme (GBM): possible therapeutics

Mir-370-3p Impairs Glioblastoma Stem-Like Cell Malignancy Regulating a Complex Interplay between HMGA2/HIF1A and the Oncogenic Long Non-Coding RNA (lncRNA) NEAT1